Search
Jul 12
The Co-CEOs of Amylyx discuss Wednesday's news that they have acquired a GLP-1 antagonist as a new pipeline asset
Josh Cohen and Justin Klee explain why they chose this program, and what the potential timeline looks like for a phase 3 trial. Plus, an...
Oct 16, 2023
Amylyx's Co-CEOs comment on Friday's European CHMP decision on their ALS therapy
Josh Cohen and Justin Klee on the negative opinion, what it means for ALS patients in Europe, and a new statistical analysis of CENTAUR.
Aug 15, 2023
Catching up with the co-founders of Amylyx on the launch of their ALS treatment
Josh Cohen and Justin Klee discuss the launch of RELYVRIO, the PHOENIX P3 trial, and reflect on the roller coaster of the last year.
.png){kind=logo}
